HIV Vaccine Trial of Vir Biotech’s New Candidate VIR-1388 Begins
XTalks
SEPTEMBER 21, 2023
announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. Vir Biotechnology, Inc.,
Let's personalize your content